Related Experiment Videos
Isoprenoids in aging and neurodegeneration
C Edlund1, M Söderberg, K Kristensson
1Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Neurochemistry International
|July 1, 1994
Summary
Alzheimer's disease shows reversed isoprenoid changes compared to normal aging, with decreased dolichol and increased ubiquinone. This indicates Alzheimer's is not premature aging, suggesting unique disease mechanisms.
Area of Science:
- Biochemistry
- Neuroscience
- Gerontology
Background:
- Aging brains exhibit increased dolichol and decreased ubiquinone levels.
- Alzheimer's disease (AD) presents distinct isoprenoid profiles compared to normal aging.
Purpose of the Study:
- To investigate and compare isoprenoid changes in the aging brain versus the Alzheimer's disease brain.
- To determine if Alzheimer's disease can be characterized as a form of premature aging based on isoprenoid metabolism.
Main Methods:
- Comparative analysis of dolichol, ubiquinone, dolichyl phosphate, and cholesterol concentrations.
- Examination of brain tissue samples from aging individuals and Alzheimer's disease patients.
Main Results:
- Alzheimer's disease brains show decreased dolichol and increased ubiquinone and dolichyl phosphate.
- Normal aging brains show increased dolichol and decreased ubiquinone.
- Cholesterol levels remained unchanged in both conditions.
Conclusions:
- Isoprenoid alterations in Alzheimer's disease differ significantly from normal aging.
- Alzheimer's disease is not a consequence of premature aging.
- Elevated dolichyl phosphate may indicate increased glycosylation, while increased ubiquinone suggests a response to oxidative stress in AD.